T Cell Immunity in Endemic Burkitt Lymphoma
地方性伯基特淋巴瘤中的 T 细胞免疫
基本信息
- 批准号:7632271
- 负责人:
- 金额:$ 37.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-06-05 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcuteAdolescentAdultAfricaAfricanAfrican Burkitt&aposs lymphomaAgeAmericanAntigensApoptosisAreaB lymphoid malignancyBurkitt LymphomaCD4 Positive T LymphocytesCD8B1 geneCellsChildChildhoodChronicCytomegalovirusDataDevelopmentDiagnosisEpidemiologic StudiesEpitopesEpstein-Barr Virus InfectionsEpstein-Barr Virus latencyEstersEtiologyEuropeEvolutionExposure toFalciparum MalariaFrequenciesGoalsHerpesviridaeHuman Herpesvirus 4IL7 geneImmuneImmunityImmunodominant EpitopesImmunologic MonitoringImmunosuppressive AgentsInfectionInfectious MononucleosisInterferonsInterleukin-10Interleukin-15Interleukin-4Interleukin-7InvestigationKenyaKnowledgeLifeLymphocyte SubsetLymphomaLyticMaintenanceMalariaMalignant Childhood NeoplasmMeasuresMediatingMemoryOutcomePathogenesisPatientsPeptide LibraryPeptidesPhosphorylationPopulationPopulations at RiskPreventionProductionProliferatingProspective StudiesRecording of previous eventsResearchRiskRoleSTAT5A geneSpecificitySurfaceT memory cellT-LymphocyteT-Lymphocyte SubsetsTestingTimeViral Load resultViral ProteinsViral load measurementVirus Diseasesbasecancer immunotherapycarboxyfluoresceincytokinecytotoxicimprovedinterleukin-15 receptormemory CD4 T lymphocytenovelpersistent EBV infectionpublic health relevanceresponsetumorvaccine development
项目摘要
DESCRIPTION (provided by applicant): The long-term goal of this proposal is to understand the etiology of endemic Burkitt's lymphoma (eBL), the most prevalent pediatric cancer in equatorial Africa. Epidemiologic studies of eBL indicate a strong association with Plasmodium falciparum malaria and Epstein-Barr virus (EBV) infections early in childhood. Although it is not known how malaria-EBV interactions increase the risk of eBL, it has been suggested that malaria-mediates suppression of EBV-specific T cell immunity. Our central hypothesis is that holoendemic malaria impairs the development and maintenance of EBV-specific effector and central memory T cell immunity. We hypothesize that two, though not mutually exclusive, mechanisms are responsible for the observed suppression of EBV immunity in African children: 1) Repeat/chronic malaria infections result in high EBV viral load, that in turn induce `CD45RA+ re-expressing' effector memory CD8+ T cell (TEMRA) which display immediate IFN-3 expression but are more susceptible to apoptosis than effector memory T cells (TEM) and/or 2) Repeat/chronic malaria infections diminish EBV-specific T cell responsiveness to homeostatic cytokines (i.e. IL-15 and IL-7). This hypothesis will be tested by examination of EBV-specific immunity in healthy Kenyan children with divergent malaria exposure histories and of eBL children. The specific aims will test the following hypotheses: Aim 1. Cumulative exposure to malaria and high EBV viral load determine the frequencies of EBV- specific CD8+ TEMRA. EBV-specific CD8+ T cells will be quantified using HLA Class I tetramers and T cell subsets defined as central memory, TCM (CD45RA-CD62L+CCR7+); effector memory, TEM (CD45RA-CD62L- CCR7-); and RA re-expressing effector memory, TEMRA (CD45RA+CD62L-CCR7-). EBV-specific T cell IFN-3 production, TCR V2 usage and proliferation by carboxyfluorescein succinimidyl ester (CFSE) dilution will be compared between the three groups of children. Aim 2. IL-15 and/or IL-7 responsiveness of EBV-specific memory T cells is impaired in children with chronic malaria exposure and in children with eBL. IL-15R1 and IL-7R1 surface expression, CFSE proliferation of EBV-specific T cells in response to cognate antigen with and without IL-15 or IL7, and responsiveness measured by STAT5 phosphorylation will be compared between the three groups of children. Aim 3. Cumulative exposure to malaria and high EBV viral load determine the frequencies of EBNA1- specific memory T cell subsets. Overlapping peptide libraries of EBNA1 will be used to identify EBNA1- specific IFN-3 expressing and proliferating memory T cell subsets. The precursor numbers of proliferating and the frequency of IFN-3 producing EBNA1-specific T cells will be compared between the three groups of children. Given that most knowledge regarding EBV T cell immunity is based on examination of asymptomatic adults or those who have had infectious mononucleosis, studies proposed here will provide novel information with respect to the evolution of EBV immunity in healthy children as well as those with eBL. PUBLIC HEALTH RELEVANCE: Burkitt lymphoma (BL) is a prevalent pediatric cancer. Understanding BL etiology will aid in the prevention of this aggressive B cell malignancy. Results from this research will ultimately improve the prospects for successful cancer immunotherapies and vaccine development for EBV-associated lymphomas such as BL.
描述(由申请人提供):本提案的长期目标是了解地方性伯基特淋巴瘤(eBL)的病因,这是赤道非洲最流行的儿科癌症。流行病学研究表明,eBL与恶性疟原虫、疟疾和EB病毒(EBV)感染在儿童早期有很强的关联。虽然目前尚不清楚疟疾-EBV相互作用如何增加eBL的风险,但已表明疟疾介导EBV特异性T细胞免疫的抑制。我们的中心假设是,全地方性疟疾损害EBV特异性效应和中枢记忆T细胞免疫的发展和维持。我们假设有两种机制(虽然不是相互排斥的)导致了非洲儿童中观察到的EBV免疫抑制:1)重复/慢性疟疾感染导致高EBV病毒载量,其依次诱导“CD 45 RA+再表达”效应记忆CD 8 + T细胞(TEMRA),其显示立即IFN-3表达,但比效应记忆T细胞(TEM)更易发生细胞凋亡,和/或2)重复/慢性疟疾感染降低EBV特异性T细胞对稳态细胞因子(即IL-15和IL-7)的反应性。这一假设将通过检查不同疟疾暴露史的健康肯尼亚儿童和eBL儿童的EB病毒特异性免疫力进行检验。具体目标将检验以下假设:目标1。累积暴露于疟疾和高EBV病毒载量决定EBV特异性CD 8 + TEMRA的频率。将使用HLA I类四聚体和T细胞亚群定量EBV特异性CD 8 + T细胞,T细胞亚群定义为中央记忆,TCM(CD 45 RA-CD 62 L + CCR 7+);效应记忆,TEM(CD 45 RA-CD 62 L-CCR 7-);和RA再表达效应记忆,TEMRA(CD 45 RA + CD 62 L-CCR 7-)。通过羧基荧光素琥珀酰亚胺酯(CFSE)稀释法比较三组儿童的EBV特异性T细胞IFN-3产生、TCR V2使用和增殖。目标2. EB病毒特异性记忆T细胞的IL-15和/或IL-7反应性在慢性疟疾暴露儿童和eBL儿童中受损将在三组儿童之间比较IL-15 R1和IL-7 R1表面表达、EBV特异性T细胞在有和没有IL-15或IL 7的情况下响应于同源抗原的CFSE增殖以及通过STAT 5磷酸化测量的响应性。目标3。疟疾的累积暴露和高EBV病毒载量决定了EBNA 1特异性记忆T细胞亚群的频率。EBNA 1的重叠肽文库将用于鉴定EBNA 1特异性IFN-3表达和增殖记忆T细胞亚群。将在三组儿童之间比较增殖的前体数量和产生IFN-3的EBNA 1特异性T细胞的频率。鉴于大多数关于EBV T细胞免疫的知识是基于对无症状成人或患有传染性单核细胞增多症的人的检查,本文提出的研究将提供关于健康儿童以及eBL儿童EBV免疫进化的新信息。公共卫生相关性:伯基特淋巴瘤(BL)是一种常见的儿科癌症。了解BL病因将有助于预防这种侵袭性B细胞恶性肿瘤。这项研究的结果将最终改善成功的癌症免疫疗法和EBV相关淋巴瘤(如BL)疫苗开发的前景。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANN M MOORMANN其他文献
ANN M MOORMANN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANN M MOORMANN', 18)}}的其他基金
A systems immunology approach to evaluate malaria vaccine performance in endemic regions of Kenya
评估肯尼亚流行地区疟疾疫苗性能的系统免疫学方法
- 批准号:
10557171 - 财政年份:2022
- 资助金额:
$ 37.01万 - 项目类别:
A systems immunology approach to evaluate malaria vaccine performance in endemic regions of Kenya
评估肯尼亚流行地区疟疾疫苗性能的系统免疫学方法
- 批准号:
10347760 - 财政年份:2022
- 资助金额:
$ 37.01万 - 项目类别:
Enhancing racial and ethnic diversity inCOVID-19 research participation through storytelling (COVIDstory)
通过讲故事增强 COVID-19 研究参与中的种族和民族多样性 (COVIDstory)
- 批准号:
10264461 - 财政年份:2020
- 资助金额:
$ 37.01万 - 项目类别:
Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma
疟疾对伯基特淋巴瘤病因中 EBV 免疫力的影响
- 批准号:
10381202 - 财政年份:2014
- 资助金额:
$ 37.01万 - 项目类别:
Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma
疟疾对伯基特淋巴瘤病因中 EBV 免疫力的影响
- 批准号:
10655570 - 财政年份:2014
- 资助金额:
$ 37.01万 - 项目类别:
Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma
疟疾对伯基特淋巴瘤病因中 EBV 免疫力的影响
- 批准号:
8767080 - 财政年份:2014
- 资助金额:
$ 37.01万 - 项目类别:
Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma
疟疾对伯基特淋巴瘤病因中 EBV 免疫力的影响
- 批准号:
10439874 - 财政年份:2014
- 资助金额:
$ 37.01万 - 项目类别:
Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma
疟疾对伯基特淋巴瘤病因中 EBV 免疫力的影响
- 批准号:
10264137 - 财政年份:2014
- 资助金额:
$ 37.01万 - 项目类别:
T Cell Immunity in Endemic Burkitt Lymphoma
地方性伯基特淋巴瘤中的 T 细胞免疫
- 批准号:
7963450 - 财政年份:2008
- 资助金额:
$ 37.01万 - 项目类别:
T Cell Immunity in Endemic Burkitt Lymphoma
地方性伯基特淋巴瘤中的 T 细胞免疫
- 批准号:
8058626 - 财政年份:2008
- 资助金额:
$ 37.01万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 37.01万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 37.01万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 37.01万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 37.01万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 37.01万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 37.01万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 37.01万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 37.01万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 37.01万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 37.01万 - 项目类别:
Operating Grants